below the 70 th percentile and 1 (poor adherence) if above the 70 th percentile. ABR was also dichotomized into no bleeds (0 ABR), the true goal of prophylaxis, versus 1 or more bleeds (1+ ABR). Results: Reported ABR ranged from 0 to 54 (median 1). There was not a significant relationship between VERITAS-Pro score and ABR. There was a significantly greater percentage of patients experiencing one or more bleeds in the VERITAS-Pro poor adherence group (86%) than in the VERITAS-Pro good adherence group (62%). ConClusions: VERITAS-Pro scores reflecting adherence are significant predictors of ABR; individuals with poor adherence on the VERITAS-Pro are more likely to have at least 1 bleed per year versus those with good adherence. However, the high percentage of patients experiencing one or more bleeds in both groups indicates that factors other than adherence may impact annualized bleed rates.
A137Objectives: Diagnosis and monitoring of lymphoma includes lymph node assessment. This study examined the association of multiple lymph node biopsies and health care resource use among lymphoma patients. MethOds: Patients with ≥ 2 claims for Hodgkin lymphoma (HL) or non-Hodgkin's (NHL) lymphoma from 1/1/06-12/31/12 were identified from a large US claims database; the index date was the first lymphoma claim date. Patients were retained if continuously enrolled in the health plan for ≥ 12 months before and after the index date, were not diagnosed with lymphoma during the pre-index period or diagnosed with cancer other than lymphoma. Health care cost and utilization were examined during the 2-year study period. Indication of receipt of biopsy included ≥ 1 claim for a lymph node biopsy (core needle, fine needle, surgical, other), pathology, or tumor excision (bone marrow biopsy not included). Health care cost and utilization was examined among patients with 0 to ≥ 3 biopsies. The cost of claims indicating biopsy was identified for each biopsy type. Results: 20,813 newly diagnosed lymphoma patients met all inclusion criteria. 16,557 (80%) had ≥ 1 claim indicating biopsy, 12,920 (62%) had ≥ 2 and 8,783 (42%) had ≥ 3. The percentage with an inpatient stay and ER visit was greatest among patients with ≥ 3 biopsies (52%, 53%) compared to patients with 2 (33%, 41%), 1 (25%, 34%), or 0 biopsies (26%, 42%). Total health care cost was greatest among patients with ≥ 3 biopsies
Objectives: To assess clinical characteristics of Multiple Sclerosis (MS) patients not on any disease modifying treatments (DMTs) in the European Union (EU) and the United States (US). MethOds: A medical chart-review study of MS patients was conducted in 2Q2017 among Healthcare providers (HCPs) in hospitals and private practices. HCPs from UK, Germany, France, Italy and Spain (5EU) and the US were recruited from a large panel to be geographically representative in each country. Medical charts of next 10 consecutive MS patients were completed by each HCP. Data on patient diagnosis, treatment patterns and disease status were collected by the HCPs. MS patients not on any DMTs, with Clinically Isolated Syndrome (CIS), Relapse Remitting MS (RRMS) and Secondary Progressive MS (SPMS) were included. Results: 831 eligible MS patients were included in the analysis (5EU: 653; US: 178). Mean age -5EU:37.1years, US: 42.4years; Female -5EU:64.2%; US: 65.7%. Key reasons for not receiving DMTs were (5EU/US): mild/early-MS (40.7%/23.6%), patient refusal (18.8%/41.0%), progressive/severe MS (13.9%/7.3%), treatment will start imminently (13.2%/10.1%), lack of efficacy of current treatment (7.4%/7.9%), pregnancy (6.6%/5,1%), authorization/ guidelines (5.1%/ 2.8%), sideeffects (2.9%/9.0%), waiting for DMTs to become available (2.3%/4.5%), drug holiday (1.5%/1.1%) and funding (0.8%/3.4%). Among patients who refused DMTs, more than half were not convinced of therapy benefits. Patients with moderate/severe disease and those with active/highly active disease were (5EU/US
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.